Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
about
The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3GSole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsA single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivityCytidine deamination induced HIV-1 drug resistanceIdentification of APOBEC3DE as another antiretroviral factor from the human APOBEC familyDDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrestIdentification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidationPosttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replicationMultiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them allEvolutionary conflicts between viruses and restriction factors shape immunitySuppression of APOBEC3-mediated restriction of HIV-1 by VifStructural Insights into HIV-1 Vif-APOBEC3F InteractionThe APOBEC3C crystal structure and the interface for HIV-1 Vif bindingThe SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complexCharacterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase componentsStructural analysis of viral infectivity factor of HIV type 1 and its interaction with A3G, EloC and EloBHIV/AIDS epidemiology, pathogenesis, prevention, and treatmentMultiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteinsIdentification of HIV-1 Vif regions required for CBF-β interaction and APOBEC3 suppressionLeveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded VifCore binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase.Evolutionarily conserved requirement for core binding factor beta in the assembly of the human immunodeficiency virus/simian immunodeficiency virus Vif-cullin 5-RING E3 ubiquitin ligase.HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinantsIdentification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to VifN-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteinsCharacterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif.Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.APOBEC3G: a double agent in defensePopulation level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions.Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
P2860
Q21245195-52752ED2-9C23-4B29-B3A3-2C0C70E51289Q24317568-367BFC60-6894-4F71-87F1-98B02FC4CB24Q24619114-104C4B03-1E02-46DF-928B-1FEC5FCB88D5Q24656551-5BD1FD86-F575-42BF-B602-5AEB0643841DQ24657298-2BC17D0C-B7E4-4CD0-A55F-A4514E3206BDQ24670173-29C3B776-B7EF-4C52-813E-DAAC89D74F6CQ24671784-E2CF0346-4AB4-4741-ACEB-DA8EAF402E55Q24672209-152C54CF-EAAB-4548-9CE6-00564BEC81FEQ24672416-25F57610-BA66-46F6-84A3-2F90CF13FAD2Q26823568-BF6E3E36-FCF1-430B-B227-BEB68C707776Q27022032-9DA959D8-5C8F-4F60-B21B-BD524B7B5F32Q27025150-5C72683C-4683-4B33-88EE-30E4F32599F4Q27321018-58B7A0E7-0114-459B-9E27-E8AC38B1D634Q27682427-94AEEC61-6F8B-4C1D-BB8C-7891D2AA6B81Q28474177-8CBD2A30-0C25-418A-8D3E-730646C6D53EQ28482052-6F71295D-AEF4-49DE-A507-17395A52C809Q28540150-8ACBBAF9-AB56-4EBA-BBC4-4C227E0382C8Q30356074-55271465-B16E-4A0D-B5CE-CBB07A72284CQ30381745-0E575C1E-185C-457B-8E8B-865CCA26692FQ33393637-CEE3762A-FA9D-4A79-B4A9-73E57BEA6016Q33583855-8C7F171A-C9E7-4D7F-BEB8-8538A85D0E0AQ33654949-F5C66893-A952-48DE-8785-944C432A9062Q33815187-76785DE3-86CE-4B61-9E9A-A8C465D4238CQ33826857-EE40A26D-4386-4632-BC97-178F7DA6FED2Q34039510-E64AD8A3-7739-469C-B3A5-D62C843A09AAQ34039514-E730107C-F775-45C9-966D-CCD4363D919BQ34059564-D2A9BB18-75FA-4FB4-BFF3-EC9F43BA2112Q34121572-9232495A-589C-452A-AA0E-18EFC315CD24Q34166447-FF5C92B4-3CB9-457E-81E7-38EA1AC3774CQ34179686-79F4861C-3C5D-49E1-8521-99786F0A33AAQ34233314-B5340253-DAD3-4434-8852-72D383F72CBEQ34266485-D55BD1E0-DC93-4D6B-B2F8-92EA39BDE5CCQ34416665-FBA508EF-45D8-468C-A8BA-BD4600E1FB28Q34493717-46965AEA-CB7E-4AB2-9A12-899A4131DD78Q34539110-6E729502-410B-4900-9A45-3E96044F2440Q34917194-67C0FEC5-A290-4A6B-A6FC-350143F23961Q35024235-0B8770A9-635E-46ED-AC53-939BF4380AAEQ35113622-EB605FE6-0722-4015-B72D-3D17E50BB670Q35214620-131056B4-099C-40CF-94F2-D8F8D5AD060EQ35451347-793356A6-F570-4B85-8EE1-72F9394F493A
P2860
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Differential requirement for c ...... ssion of APOBEC3G and APOBEC3F
@nl
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@ast
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@en
type
label
Differential requirement for c ...... ssion of APOBEC3G and APOBEC3F
@nl
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@ast
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@en
prefLabel
Differential requirement for c ...... ssion of APOBEC3G and APOBEC3F
@nl
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@ast
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@en
P2093
P2860
P1433
P1476
Differential requirement for c ...... sion of APOBEC3G and APOBEC3F.
@en
P2093
Chunjuan Tian
Rongzhen Xu
Xianghui Yu
Xiao-Fang Yu
P2860
P304
P356
10.1128/JVI.80.6.3112-3115.2006
P407
P577
2006-03-01T00:00:00Z